the different components and may reduce the risk of animal-to-human infection, but have taken several steps in development to mimic the complexity of natural surfactants [4] . CHF 5633 is such a new third-generation synthetic surfactant containing 0.2% SP-B analog and 1.5% SP-C analog mixed with a DPPC:palmitoyloleoylphosph atidylglycerol ratio of 1: 1 that has been tested in humans (NCT01651637; NCT02452476).
Surfactant Dosing and Redosing
Term infants have a surfactant storage pool of approximately 100 mg/kg of surfactant, while preterm infants have an estimated pool size of 4-5 mg/kg at birth [2] . In addition to the pool size, positive end expiratory pressure improves pulmonary distribution and augments the surface tension-lowering effects of surfactant [5] [6] [7] .
Repetitive doses of exogenous surfactant administered as a bolus have been studied. A Cochrane Review demonstrated that a strategy of allowing multiple doses of natural surfactant rather than a single dose further reduces the risk of pneumothorax (RR 0.51, 95% CI 0.3-0.88) and there is a trend towards a reduction in mortality. However, the studies included in this meta-analysis were performed in the early 1990s with lower use of antenatal corticosteroids and longer ventilation periods. Recent guidelines advise only the administration of a second dose if there is ongoing evidence of respiratory distress syndrome (RDS), such as the need for continued mechanical ventilation or oxygen dependence [8, 9] .
However, the size of the first dose of surfactant is of clinical importance. Doses between 50 mg/kg of beractant (phospholipid concentration 50 mg/mL) and 200 mg/kg of poractant alfa (80 mg/mL) have been studied. Infants who received 50 mg/kg of beractant compared to 100 mg/kg were more often non-responders and in need of a second dose of surfactant [10] . Other clinical studies compared 100 mg/kg doses of 1 product with 100 and 200 mg/kg doses of another product [11] . The concentration of surfactant, however, determines the amount of surfactant that can be deposited as a bolus since the volume of the trachea of a small preterm infant is restricted. Therefore, doses beyond 100 mg/kg could only be studied with the more concentrated poractant alfa. Post hoc analysis of studies that compared beractant and poractant alfa demonstrated that poractant alfa administered at high doses of 200 mg/kg compared to a lower dose of 100 mg/kg led to increased survival and decreased intraventricular hemorrhage (IVH). Besides, redosing was needed less frequently [11] [12] [13] [14] , probably due to the longer half-life of DPPC when administered at the higher 200 mg/kg dose.
The surfactant dosage in less invasive surfactant administration techniques (which are discussed later) has not yet been studied. However, it must be taken into account that when surfactant is administered with a feeding tube a significant amount (11%) of material is lost in the tube [15] . The dose dependency of the clinical response with a minimally invasive surfactant technique was confirmed in a recent study by Dargaville et al. [16] , where all infants who received poractant alfa at a dose of 200 mg/ kg did not have to be ventilated in the first 72 h of life.
When Should Surfactant Be Given?
The first clinical trials with surfactant were performed in preterm infants who were ventilated because of RDS. Less than half of these infants received antenatal corticosteroids. These studies demonstrated that early surfactant administration (at FiO 2 <0.45) was superior to late (FiO 2 >0.45) administration [17] [18] [19] . This led to a strategy of early intubation of very preterm infants in the delivery room and prophylactic surfactant administration from the 1990s onwards.
However, empirical evidence that continuous positive airway pressure (CPAP) treatment was associated with low rates of bronchopulmonary dysplasia (BPD) led to renewed interest in CPAP. The use of CPAP, antenatal corticosteroids (which attenuate RDS and the need for exogenous surfactant), and the treatment of younger infants with very vulnerable lungs have created a dilemma in the delivery room [20] : is it better to intubate these infants and give prophylactic surfactant or manage them on CPAP?
Several large clinical trials (COIN, SUPPORT, and VON-DRM) have addressed this question [21] [22] [23] . It was concluded that it was better to start with CPAP support in the delivery room if possible and intubate and administer surfactant only to infants with signs of RDS [21] [22] [23] .
Other studies compared CPAP to prophylactic surfactant treatment with the Intubate-Surfactant-Extubate (INSURE) approach. During INSURE, infants are intubated, receive surfactant, and are supposed to be immediately extubated to minimize mechanical ventilation, if necessary antagonising any sedation that was used for intubation. These studies also did not find a benefit of prophylactic surfactant with INSURE over CPAP [21, 24, 25] . A possible explanation may be that even short peri-ods of mechanical ventilation can damage the vulnerable lung. Many of the infants in whom INSURE was performed were ventilated for a longer period [26] . Moreover, INSURE turned out to be difficult to implement in other neonatal units. Many, mainly extremely preterm infants, who were treated with INSURE failed to be extubated after surfactant administration, leading to a longer time on ventilation. Brix et al. [26] demonstrated that more than 60% of preterm infants treated with INSURE failed to be extubated 2 h after the procedure. Meta-analyses have demonstrated that prophylactic INSURE did not lead to a higher survival without BPD [27, 28] . A new modified INSURE with an alveolar recruitment manoeuvre before surfactant administration is currently being investigated [29] .
Meta-analyses that have incorporated this new evidence demonstrate that selective use of surfactant versus prophylactic use of surfactant leads to a decrease in BPD and/or death [27] . Recent evidence still demonstrates that early rescue surfactant (<2 h after birth) versus late rescue surfactant (>2 h after birth) is associated with a reduction in BPD and/or death [30] . Therefore, the American Academy of Pediatrics and the European guidelines on surfactant administration advise stabilization of preterm infants on CPAP and, if necessary, the administration of surfactant as early rescue therapy, preferably within 2-3 h after birth [8, 9] .
The clinical dilemma which arises from this practice is that a subgroup of infants fail CPAP therapy and have to be intubated at a later time. These infants miss the advantages of early surfactant and suffer a higher incidence of BPD and IVH [31] . Various studies have investigated whether CPAP failure can be predicted [31] [32] [33] [34] . Predictors of CPAP failure included male sex and low birth weight, but most importantly FiO 2 above 0.30-0.35 in the first 2 h of life. The availability of new techniques of surfactant administration may make it easier to provide earlier treatment.
New Techniques of Surfactant Administration
New techniques of surfactant administration in combination with CPAP may offer a way to avoid mechanical ventilation completely [8, 9, 35] ( Fig. 1 ) . A less invasive technique of administering surfactant with a small cath- eter instead of an endotracheal tube to infants breathing spontaneously may combine the benefits of CPAP (which avoids mechanical ventilation) and early surfactant treatment [36] . The first feasibility study was performed by Kribs et al. [37] in Cologne. In this procedure, named less invasive surfactant administration (LISA), a thin catheter is placed in the trachea with the aid of Magill forceps under direct laryngoscopy. This procedure is embedded in a whole package of interventions aimed at the avoidance of positive pressure ventilation, especially during transition and the first 72 h of life [36] . This package includes antenatal steroids, early CPAP, and caffeine treatment in the delivery room [38] . During this technique CPAP is continued as the distribution of surfactant is dependent on alveolar recruitment [7] . LISA leads to an immediate increase in end-expiratory lung volume and oxygenation in preterm infants on CPAP [39] . LISA may lead to better surfactant distribution and better lung compliance as infants keep spontaneously breathing [40] . Surfactant distribution in LISA-treated lambs was compared to lambs who were intubated and received surfactant [41] . Although in the LISA-treated lambs surfactant deposition in the lungs was lower and surfactant distribution differed slightly, with less surfactant being delivered to the right upper lung, oxygenation improved in a similar way compared to the lambs who were intubated and received surfactant.
The first randomised trial (AMV study) of the German Neonatal Network (GNN), which included preterm infants born at gestational age 26-29 weeks, demonstrated a risk reduction in the need for mechanical ventilation during the first 72 h [42] . Besides, infants treated with LISA had fewer days on mechanical ventilation and less oxygen need at the 28th day of life compared to infants who were treated conventionally. As the infants were recruited immediately after birth, not all needed surfactant [42] .
In a later randomised trial (NINSAPP study), infants with a gestational age of 24-28 weeks in need of surfactant were included. This study did not show a reduction in BPD and/or death as the primary endpoint. However, the LISA-treated infants showed a higher rate of survival without major complications (BPD, NEC, pneumothorax, and severe IVH grade 3/4) compared to the control group. In particular, the relative reduction of 50% in severe IVH was striking. Although not a primary endpoint, this study confirmed a large reduction in the need for mechanical ventilation during the first days of life [43] .
Large observational studies supported these findings but they also demonstrated a reduction in BPD [44, 45] .
However, there is still variability in the application of this technique regarding indications, catheter type, redosing, and the use of premedication [46, 47] .
In 2011 the procedure was modified by Dargaville et al. [48] , who used a rigid adult vascular catheter (16-G Angiocath; BD Medical, Sandy, UT, USA) to avoid use of the Magill forceps. This method was named minimally invasive surfactant therapy (MIST) and was evaluated in 2 observational trials showing similar results to the first LISA studies [48, 49] . A large international multicentre trial (OPTIMIST) using this method is currently recruiting (NCT02140580).
Although LISA and MIST vary in certain aspects, recent meta-analyses combining the different trials with these methods demonstrated a reduction in BPD and/or death in infants (RR 0.75, 95% CI 0.59-0.94) who were treated with LISA/MIST [50] [51] [52] . The absence of premedication during placement of the catheter in infants receiving LISA/MIST is still a point of intense debate. A recent retrospective study compared the administration of propofol (1 mg/kg) to no sedation in 38 preterm infants, of whom 23 received MIST [53] . The administration of propofol was left at the discretion of the attending neonatologist. Infants who received propofol showed lower pain scores, but more needed positive pressure ventilation and/or intubation. Therefore, administration of premedication may diminish the positive effects of LISA/ MIST.
The laryngeal mask (LMA) is a supraglottic device that is usually used to apply positive pressure ventilation for a short time. In 2004, surfactant administration using a LMA was first described in a case report by Brimacombe et al. [54] . A pilot randomized controlled trial in 26 preterm infants with birth weight >1,200 g compared surfactant given by LMA to CPAP and found a marked decrease in oxygen requirement in infants who received surfactant via LMA [55] . Other trials compared surfactant via LMA to the INSURE method. Sadeghnia et al. [56] performed a study in infants with a birth weight over 2,000 g and observed better oxygenation in infants who received surfactant via LMA, but no difference in the need for mechanical ventilation.
Pinheiro et al. [57] investigated surfactant via LMA versus INSURE in infants with birth weights >1,000 g. Treatment failure was decreased in the LMA group (30%) compared to the INSURE group (77%). This might be due to the fact that failure was defined as the need for mechanical ventilation or antagonising drugs. Infants with surfactant per LMA did not receive premedication, allowing them to keep breathing spontaneously. Although the trial demonstrated that placement of the LMA was perceived as easy by experienced users, more than 1 attempt was often needed to place it correctly. In addition, surfactant reflux and coughing were frequently observed [36] . LMA placement has not yet been proven feasible in the smallest of infants who most profit from less invasive surfactant administration methods.
To optimize the technique of administering surfactant less invasively, some clinical scientists have combined different methods or tools. Recently, a study (CALMEST) was published which combined use of an LMA as a guide for a LISA catheter to administer surfactant [58] . Also, Poets and colleagues [59] developed a special soft catheter to administer surfactant less invasively without Magill forceps.
These approaches reduce the size of the device that is put through the vocal cords but do not eliminate it. Surfactant administration by nebulization is therefore in theory the most elegant, as it is truly non-invasive. However, this technique has many practical issues: the particle size has to be very small (0.5-2.0 μm), the substance must remain intact during nebulization, and the loss/misplacement of the expensive surfactant in the upper airways and/or oesophagus must be kept to a minimum in order to reduce costs. Besides, as the nebulized surfactant only distributes to the ventilated parts of the lung, nebulization may lead to an inhomogeneous surfactant distribution.
Different nebulizers have been tested in animal models and in clinical settings for this purpose. Older studies with jet nebulizers with very low pulmonary deposition (<1%) of surfactant do not show convincing clinical results [36, 60, 61] . Recently, the emergence of vibrating perforated membrane nebulizers have provided significant improvements for aerosolization. Aerosol droplets are generated by a perforated vibrating mesh which can be adjusted to the physicochemical properties of the drug. Consequently, these devices markedly increase the proportion of aerosolized drug delivered to the patient [62] . Surfactant nebulization with perforated membrane nebulizers was tested in a feasibility trial [63] and in an animal model. Longer nebulization of higher doses of surfactant in humidified air improved oxygenation and lung mechanics. Surfactant was delivered to all lung lobes, with a preference to the lower lobes when given at high doses [64] . However, the yield of the nebulized surfactant into the lungs was very poor. Pillow and Minocchieri [62] performed a clinical trial in infants >29 weeks' gestational age (ANZCTR 12610000857000) but the results have not been published yet. Currently, a phase II single-centre study is recruiting infants with RDS to investigate nebulized surfactant (NCT 02294630).
Surfactant in Combination with Medication Administration
Budesonide As inflammation plays a major part in the development of BPD, corticosteroid therapy has been investigated extensively for its treatment and prevention. Due to side effects and the lack of clinical evidence on the drug, dose, duration, and start of therapy, more organ-directed corticosteroid therapy with inhaled budesonide has been investigated, with conflicting results on mortality [65] . However, surfactant may be a good vehicle for corticosteroid delivery to the lung. Yeh et al. [66] performed a pilot study in which 116 very low birth weight infants with severe RDS needing mechanical ventilation were treated with surfactant combined with budesonide. This treatment resulted in lower combined BPD and death rates (31.7%) compared to surfactant only (60.7%, p = 0.003). In a 2-3 year follow-up no neurocognitive adverse effects were detected after combined surfactant and budesonide treatment. A recent trial of 265 low birth weight infants, also by Yeh and colleagues [67] , confirmed these promising results. In the intervention group (surfactant with budesonide) the combined BPD and death rate was 42% compared to 66% in controls (surfactant alone). The number needed to treat was 4.1 (2.8-7.8, p < 0.001) and no adverse effects were noticed [68] . This approach has not been studied with less invasive surfactant administration techniques.
Future Directions
The following aspects may form the focus of future research. Early identification of infants who need surfactant is of importance, and the disadvantages of late surfactant administration should be prevented. Furthermore, as new methods of minimally invasive surfactant administration are emerging, prophylactic surfactant with LISA may have advantages over CPAP with rescue administration of surfactant by LISA in very preterm infants <26 weeks' gestational age, who are very often in need of surfactant. However, this has to be investigated in large clinical trials.
The best minimally invasive method of surfactant administration has to be identified. Currently there is a large variability between indications and methods for less invasive surfactant treatment. We need to identify the groups of patients who benefit most or who do not benefit from this technique, the right dose of surfactant, type of surfactant, indication for repeating surfactant administration (intubation or reperforming less invasive technique), use 413 of catheters (with the development and testing of new special catheters for less invasive surfactant administration), and the use of premedication, in order to get the most out of this innovation for the appropriate patient population.
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